Stability testing found that a batch of carbidopa/levodopa was "superpotent."
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has recalled a batch of its generic Parkinson's combination drug treatment carbidopa/levodopa because of concern that it may contain too much active pharmaceutical ingredient.
The company said that the Class II recall involved 3,881 bottles of 25 or 100mg carbidopa/levodopa. Teva added that stability testing found that the product might be "superpotent." The voluntary recall is for the entire US.
A class II recall as defined by the US Food and Drug Administration (FDA) means that use of a drug could cause temporary damage to health.
Published by Globes [online], Israel business news - www.globes-online.com - on August 28, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014
Teva